C.D. de Kroon
Leiden University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by C.D. de Kroon.
British Journal of Obstetrics and Gynaecology | 2007
H van Dongen; C.D. de Kroon; C.E. Jacobi; J.B.M.Z. Trimbos; Frank Willem Jansen
Background This study was conducted to assess the accuracy and feasibility of diagnostic hysteroscopy in the evaluation of intrauterine abnormalities in women with abnormal uterine bleeding.
British Journal of Obstetrics and Gynaecology | 2008
H van Dongen; C.D. de Kroon; Sahm Van Den Tillaart; Leoni A. Louwé; Gcm Trimbos‐Kemper; Frank Willem Jansen
Objective The purpose of this study was to compare patient discomfort during saline infusion sonography (SIS) and office hysteroscopy performed according to a vaginoscopic approach.
Maturitas | 2016
M.D.J.M. van Gent; L.M. Romijn; K.E. van Santen; J.B.M.Z. Trimbos; C.D. de Kroon
BACKGROUND AND AIMS Survival after radical hysterectomy (RH) for early-stage cervical cancer is good. Hence quality of life (QOL) after treatment is an important issue. Nerve-sparing radical hysterectomy (NSRH) improves QOL by selectively sparing innervation of bladder, bowel and vagina, reducing therapy-induced morbidity. However, the oncological outcome and the functional outcome after NSRH are subjects of debate. We aim to present the best possible evidence available regarding both QOL and survival after NSRH in early-stage cervical cancer. METHODS Systematic review and meta-analysis on studies comparing NSRH and RH. RESULTS Forty-one studies were included, and 27 were used for the meta-analysis. There was no difference in 2-, 3- and 5-year overall survival: the risk ratios (RRs) were respectively 1.02 (95% CI 0.99-1.05, n=879), 1.01 (95% CI 0.95-1.08, n=1324) and 1.03 (95% CI 0.99-1.08, n=638). No difference was found in 2-, 3- and 5-year disease-free survival: RR 1.01 (95% CI 0.95-1.05, n=1175), 0.99 (95% CI 0.94-1.03, n=1130) and 1.00 (95% CI 0.95-1.06, n=933) respectively. Post-operative time to micturition was significantly shorter in the NSRH group: standardized mean difference (SMD) -0.84 (CI 95% -1.07 to -0.60). CONCLUSIONS NSRH can be considered safe and effective for early-stage cervical cancer since short- and long-term survival do not differ from those of conventional RH, while bladder function after NSRH is significantly less impaired.
Clinical Oncology | 2018
N.M.A. Van der Hoeven; K. Van Wijk; S.E. Bonfrer; Jogchum J. Beltman; Leoni A. Louwé; C.D. de Kroon; C.J. van Asperen; Katja N. Gaarenstroom
The optimal management of breast cancer susceptibility gene (BRCA)1/2 carriers with isolated serous tubal intraepithelial carcinoma (STIC) found at risk-reducing salpingo-oophorectomy (RRSO) is unclear. The prevalence of occult carcinoma and STIC in a consecutive series of BRCA1/2 carriers undergoing RRSO is reported. The outcome of staging procedures in BRCA1/2 carriers with isolated STIC at RRSO as well as the relationship between staging, chemotherapy treatment and risk of recurrence was assessed via a systematic review of the literature. Our series included 235 BRCA1/2 carriers who underwent RRSO. Federation of Gynaecology and Obstetrics stage IA carcinoma or STIC was found at RRSO in three (1.3%) and two (0.9%) patients, respectively. A systematic review of the literature included 82 BRCA1/2 carriers with isolated STIC found at RRSO. In 13/82 (16%) cases with STIC, staging was reported. In none of these cases staging revealed more advanced disease. Recurrent disease was found in four of 36 patients with reported follow-up. The estimated risk of recurrence in patients with isolated STIC at RRSO was about 11% (95% confidence interval 3-26%) after a median follow-up of 42 months (range 7-138). No recurrences were reported in those patients with STIC at RRSO who underwent staging or received chemotherapy. We found 1.3% occult carcinoma and 0.9% STIC at RRSO in our cohort of BRCA1/2 carriers. A systematic review of the literature suggests that additional treatment after RRSO, i.e. staging and/or chemotherapy, is associated with a lower risk of recurrence. However, data on staging and follow-up are limited.
Human Reproduction | 2004
C.D. de Kroon; H.A.G.M. van der Sandt; J.C. van Houwelingen; F. W. Jansen
Human Reproduction | 2003
C.D. de Kroon; J.C. van Houwelingen; J.B. Trimbos; Frank Willem Jansen
European Journal of Cancer | 2017
M.M. de Jonge; Antien L. Mooyaart; Maaike P.G. Vreeswijk; C.D. de Kroon; T. van Wezel; C.J. van Asperen; Vincent T.H.B.M. Smit; Olaf M. Dekkers; Tjalling Bosse
Supportive Care in Cancer | 2017
Rinske M. Bakker; Jan Willem M. Mens; H.E. de Groot; Charlotte C. Tuijnman-Raasveld; C. Braat; W. C. P. Hompus; J. G. M. Poelman; M.S. Laman; L.A. Velema; C.D. de Kroon; H. C. van Doorn; Carien L. Creutzberg; M.M. ter Kuile
European Journal of Cancer | 2015
I. Van Gool; Florine A. Eggink; Luke Freeman-Mills; Ellen Stelloo; Emanuele Marchi; Claire Palles; M. de Bruyn; Remi A. Nout; C.D. de Kroon; M. Osse; Paul Klenerman; Carien L. Creutzberg; I P M Tomlinson; Vincent T.H.B.M. Smit; Hans W. Nijman; Tjalling Bosse; David N. Church
Gynecological Surgery | 2014
Arh Twijnstra; Mathijs D. Blikkendaal; Src Driessen; E.W. van Zwet; C.D. de Kroon; Frank-Willem Jansen